-
Health todayCancer new
Wildfire smoke is linked to shorter survival in older US lung cancer patients
A SEER-Medicare cohort of 414,016 patients aged 65 or older with lung cancer found shorter overall survival with higher long-term exposure to wildfire-related fine particles.
Peer-reviewed -
Health todayCancer new
Blood test used with the standard marker CA19-9 detected early-stage pancreatic cancer
A prospective study of 1,785 people across four countries reports that an exosome-based blood test, used with the standard marker CA19-9, detected early-stage pancreatic cancer with high sensitivity.
Peer-reviewed -
Health todayCancer confirms
Vaccinated Spanish women have less HPV 16/18 and fewer high-grade cervical lesions
Among 908 women in population-based cervical screening in Spain, HPV 16/18 was detected in 0.76% of vaccinated women as compared to 5.5% of unvaccinated women.
Preprint · not peer-reviewed -
Health todayCancer new
No study has yet followed snus or e-cigarette users through chemotherapy
A review to June 2026 found no study of how snus or e-cigarettes affect response to chemotherapy, and the one laboratory signal of drug resistance did not replicate.
Peer-reviewed -
Health todayCancer confirms
Modelled estimates put 10.6m new cancers at 65+ in 2022, rising 75% by 2036
A secondary analysis of GLOBOCAN 2022 and GBD 2021 estimates reports 10.6 million new cancer cases and 6.0 million cancer deaths among adults aged 65 and over in 2022, with the modelled case count projected to rise 75.5% by 2036 as populations age.
Peer-reviewed -
Health todayCancer contradicts
Reanalysed mammography trials are compatible with breast cancer overdiagnosis below 5%
A reanalysis of randomised mammography trials, benchmarked against Denmark's Funen screening programme, found the extra cancers detected compatible with breast cancer overdiagnosis below 5%, against published estimates up to 50%.
Peer-reviewed -
Data, models and systemsCancer new
Deaths mentioning lung metastases reached their highest recorded US rate in 2024
US age-adjusted mortality involving secondary malignant neoplasm of the lung fell to 7.22 per 100,000 in 2008, then rose to 11.38 in 2024, the highest level recorded.
Preprint · not peer-reviewed